Comparison of Nucleoside Reverse Transcriptase Inhibitor Use as Part of First-Line Therapy in a Serbian and a UK HIV Clinic

REFERENCES

• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853–860.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observa-tional study. Lancet. 2003;362:22–29.
   PubMed Web of Science ®Google Scholar
• Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database Syst Rev. 2006;2:CD004535.
   PubMed Web of Science ®Google Scholar
• Nuesch R, Srasuebkul P, Ananworanich J, et al. Monitor-ing the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother 2006;58(3):637–644.
   PubMed Web of Science ®Google Scholar
• Matheron S, Massip P, Trepo C, et al. Metabolic and clinical evaluation of lipodystrophy syndrome (LD) in HIV-1-infected adults receiving initial HAART with or without a protease inhibitor (Pp: 48 week data from the CNAF3007 study. In: Program and abstracts of the 8th Conference on Retrovi-ruses and Opportunistic Infections; 2001. Abstract 670.
   Google Scholar
• Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002;16(18):2447–2454.
   PubMed Web of Science ®Google Scholar
• Periard D, Telenti A, Sudre P, et al. Atherogenic dys-lipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999;100(7):700–705.
   PubMed Web of Science ®Google Scholar
• Herman JS, Ives NJ, Nelson M, Gazzard BG, Easterbrook PJ. Incidence and risk factors for the development of indinavir-associated renal complications. J Antimicrob Chemother 2001;48:355–360.
   PubMed Web of Science ®Google Scholar
• Dieleman JP, van Rossum AMC, Stricker BCH, et al. Per-sistent leukocyturia and loss of renal function in a prospec-tively monitored cohort of HIV-infected patients treated with indinavir. J Acquir Immune Defic Syndr 2003;32:135–142.
   PubMed Web of Science ®Google Scholar
• Easterbrook P, Phillips AN, Hill T, et al. Patterns and predic-tors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med. 2008;9(1):47–56.
   PubMed Web of Science ®Google Scholar
• Semba RD, Shah N, Vlahov D. Risk factors and cumulative incidence of anaemia among HIV-infected injection drug users. Int J STD AIDS. 2002;13(2):119–123.
   PubMed Web of Science ®Google Scholar
• White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect. 200177(3):158–173.
   Web of Science ®Google Scholar
• Smith CJ, Sabin CA, Lampe FC, et al. The relationship between CD4 cell nadirs and the toxicity profiles of antiret-roviral regimens. Antiviral Ther 2005;10:459–467.
   PubMed Web of Science ®Google Scholar
• Rossero R, Asmuth DM, Grady JJ, et al. Hydroxyurea in combination with didanosine and stavudine in antiretrovi-ral-experienced HIV-infected subjects with a review of the literature. Int J STD AIDS. 2003;14(5):350–355.
   PubMed Web of Science ®Google Scholar
• Moore RD, Keruly JC, Chaisson RE. Incidence of pancrea-titis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS. 2001;15(5):617–620.
   PubMed Web of Science ®Google Scholar
• Dragovic G, Milic N, Jevtovic DJ. Incidence of acute pan-creatitis and nucleoside reverse transcriptase inhibitors usage. Int J STD AIDS. 2005;16:427–429.
   PubMed Web of Science ®Google Scholar
• Dragovic G, Jevtovic DJ. Nucleoside reverse tran-scriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients. Antiviral Chemother. 2003;14:281–284.
   PubMedGoogle Scholar
• Gazzard B, for the BHIVA writing committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2008;9:795–848.
   PubMed Web of Science ®Google Scholar
• Hammer SM,Saag MS, Schechter M, et al. Treatmentforadult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296(7):827–843.
   PubMed Web of Science ®Google Scholar
• Clumeck N, Pozniak A, Raffi F, EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9(2):65–71.
   PubMed Web of Science ®Google Scholar
• Bollerup AR, Donoghoe MC, Lazarus JV, Nielsen S, Matic S. Access to highly active antiretroviral therapy (HAART) in the WHO European Region 2003-2005. Scand J Public Health. 2008;36:183–189.
   PubMed Web of Science ®Google Scholar
• Sabin CA, Lampe F, Chaloner C, et al. An audit of antiret-roviral treatment use in HIV-infected patients in a London clinic. HIV Med. 2003;4(2):87–93.
   PubMedGoogle Scholar
• Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly active antiret-roviral therapy in developing countries. Clin Infect Dis. 2007;45(8)1 093–1101.
   Web of Science ®Google Scholar
• Oyugi JH, Byakika-Tusüme J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21(8):965–971.
   PubMed Web of Science ®Google Scholar
• Canestri A, Sow PS, Vray M, et al. Poor efficacy and toler-ability of stavudine, didanosine, and efavirenz-based regi-men in treatment-naive patients in Senegal. MedGenMed. 2007;9(4):7.
   PubMedGoogle Scholar
• Rey D, Krebs M, Partisani M, et al. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2006;43(5):530–534.
   PubMed Web of Science ®Google Scholar
• Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV Observational Database: baseline and retro-spective data. J Acquir Immune Defic Syndr. 2005;38(2): 174–179.
   PubMed Web of Science ®Google Scholar
• Hofer CB, Schechter M, Harrison LH. Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2004;36(4):967–971.
   PubMed Web of Science ®Google Scholar
• Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 2003;32:48–56.
   Google Scholar
• Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais J-P, Viard JP. Lipodystrophic syndromes and hyperlipi-demia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr Hum Retrovirol. 2001;27:443–449.
   Google Scholar
• van der Valk M, Gisolf EH, Wit FW, Japour A, Weverling GJ, Danner SA. Increased risk of lipodystrophy when nucleo-side analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 200115(7):847–855.
   Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of periph-eral lipodystrophy, hyperlipidaemia and insulin resis-tance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58.
   PubMed Web of Science ®Google Scholar
• Sabin CA, Smith CJ, Gumley H, et al. Late presenters in the era of HAART: uptake of and responses to antiretroviral therapy. AIDS. 2004;18(15):2145–2151.
   PubMed Web of Science ®Google Scholar
• UNAIDS. 2006. http://data.unaids.org/pub/Report/2006/2006_country_progress_report_serbia_en.pdf.
   Google Scholar